{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:04:17Z","timestamp":1792789457375,"version":"4.5.0"},"reference-count":24,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The National Institutes of Health","award":["K12-AR084222"],"award-info":[{"award-number":["K12-AR084222"]}]},{"award":["K12-AR084222"],"award-info":[{"award-number":["K12-AR084222"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Mayo Clinic Center for Women\u2019s Health Research","id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>To compare the 1-year risk of biliary\/pancreatic adverse events among patients with obesity and type 2 diabetes treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus dipeptidyl peptidase-4 inhibitors (DPP-4i), and to directly compare tirzepatide with semaglutide. Methods: We conducted a retrospective propensity score-matched cohort study using the TriNetX Global Collaborative Network. Adults with obesity and type 2 diabetes without prior biliary or pancreatic disease were included. Two prespecified comparisons were performed: GLP-1RA (semaglutide or tirzepatide) versus DPP-4i, and tirzepatide versus semaglutide. The primary outcome was incident cholelithiasis at 1 year. Secondary outcomes included cholecystitis, cholangitis, acute pancreatitis, and cholecystectomy. Hazard ratios (HRs) were estimated using Cox proportional hazards models. Results: After matching, 281,283 patients were included in each GLP-1RA and DPP-4i cohort, and 242,876 patients in each tirzepatide and semaglutide cohort. Compared with DPP-4i, GLP-1RA therapy was associated with lower risks of cholelithiasis (1.02% vs. 1.16%; HR 0.92, 95%CI 0.87\u20130.96), cholecystitis (HR 0.88, 95%CI 0.79\u20130.98), cholangitis (HR 0.46, 95%CI 0.36\u20130.58), acute pancreatitis (HR 0.68, 95%CI 0.61\u20130.76), and cholecystectomy (HR 0.51, 95%CI 0.38\u20130.69). In the head-to-head comparison, semaglutide was associated with higher risks of cholelithiasis (HR 1.11, 95%CI 1.05\u20131.18) and cholecystitis (HR 1.22, 95%CI 1.10\u20131.37) compared with tirzepatide, while risks of pancreatitis, cholangitis, and cholecystectomy did not differ significantly. Conclusions: In this large real-world study, GLP-1RA therapy was associated with lower risks of biliary and pancreatic events compared with DPP-4i. Tirzepatide demonstrated a modestly more favorable biliary safety profile than semaglutide, supporting the overall hepatobiliary safety of contemporary GLP-1-based therapies.<\/jats:p>","DOI":"10.3390\/jcm15208027","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:19:16Z","timestamp":1792142356000},"page":"8027","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biliary and Pancreatic Safety of Incretin-Based Therapies in Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Comparison of Tirzepatide, Semaglutide, and DPP-4 Inhibitors"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9389-6795","authenticated-orcid":false,"given":"Wissam","family":"Ghusn","sequence":"first","affiliation":[{"name":"Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Sasha-Jane","family":"Abi-Aad","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saint Louis University, St. Louis, MO 63104, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2322-7334","authenticated-orcid":false,"given":"Maria Daniela","family":"Hurtado","sequence":"additional","affiliation":[{"name":"Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.mayocp.2023.05.026","article-title":"Obesity: A Review of Pathophysiology and Classification","volume":"98","author":"Busebee","year":"2023","journal-title":"Mayo Clin. Proc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.gtc.2016.07.010","article-title":"The Impact of Obesity on Gallstone Disease, Acute Pancreatitis, and Pancreatic Cancer","volume":"45","author":"Conwell","year":"2016","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease","volume":"152","author":"Tailleux","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100045","DOI":"10.1016\/j.obpill.2022.100045","article-title":"Weight-centric treatment of type 2 diabetes mellitus","volume":"4","author":"Ghusn","year":"2022","journal-title":"Obes. Pillars"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: A prespecified analysis of the SELECT trial","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100127","DOI":"10.1016\/j.obpill.2024.100127","article-title":"Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks","volume":"12","author":"Ghusn","year":"2024","journal-title":"Obes. Pillars"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: A narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamainternmed.2022.0335","article-title":"Glucagon-Like Peptide-1 Receptor Agonists-How Safe Are They?","volume":"182","author":"Haider","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of Glucagon-Like Peptide-1 Receptor Agonist Use with Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.2337\/dc25-1840","article-title":"Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients with Type 2 Diabetes","volume":"48","author":"Fang","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2016.1531","article-title":"Association of Bile Duct and Gallbladder Diseases with the Use of Incretin-Based Drugs in Patients with Type 2 Diabetes Mellitus","volume":"176","author":"Faillie","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs. Tirzepatide for Weight Loss in Adults with Overweight or Obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_15","first-page":"1032","article-title":"Gallstones, gallbladder disease, and pancreatitis: Cross-sectional and 2-year data from the Swedish Obese Subjects (SOS) and SOS reference studies","volume":"98","author":"Torgerson","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100114","DOI":"10.1016\/j.ajmo.2025.100114","article-title":"GLP-1 Receptor Agonists Initiation and Risk of Acute Pancreatitis and Pancreatic Cancer: A Real-World Comparative Study","volume":"14","author":"Faour","year":"2025","journal-title":"Am. J. Med. Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis","volume":"169","author":"Chiang","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ayoub, M., Chela, H., Amin, N., Hunter, R., Anwar, J., Tahan, V., and Daglilar, E. (2025). Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of TypeDiabetes Patients in the United States: A Propensity Score-Matched Analysis. J. Clin. Med., 14.","DOI":"10.3390\/jcm14030944"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Conforti, A., Lucchetti, L., Ciampa, F., Bonifacio, M., Musorrofiti, M.G., Cipolloni, V., and Messina, F. (2026). Beyond the Scale: Changes in Pain, Physical Function (WOMAC), and Low-Grade Inflammation Following Semaglutide Treatment in Patients with Knee Osteoarthritis\u2014Results from a Six-Month Real-World Cohort. J. Clin. Med., 15.","DOI":"10.3390\/jcm15155876"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., and Madej, P. (2022). The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084334"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41366-023-01456-5","article-title":"Weight loss and cardiovascular disease risk outcomes of semaglutide: A one-year multicentered study","volume":"48","author":"Ghusn","year":"2024","journal-title":"Int. J. Obes."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptidereceptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40264-024-01434-4","article-title":"Dipeptidyl Peptidase-4 Inhibitors and the Risk of Gallbladder and Bile Duct Disease Among Patients with Type 2 Diabetes: A Population-Based Cohort Study","volume":"47","author":"Shapiro","year":"2024","journal-title":"Drug Saf."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kazi, M.A.I., Singh, S., and Haq, N. (2025). Guts, Glucose, and Gallbladders: The Protective Role of GLP-1\/GIP Receptor Agonists Against Biliary Complications in Patients with Type 2 Diabetes and Inflammatory Bowel Disease. J. Clin. Med., 14.","DOI":"10.3390\/jcm14248882"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/20\/8027\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:17:15Z","timestamp":1792297035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/20\/8027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":24,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15208027"],"URL":"https:\/\/doi.org\/10.3390\/jcm15208027","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]}}}